Detail akcie Inhibrx Bio Rg-WI online

Business Summary: Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Inhibrx Biosciences Inc revenues increased from $100K to $1.3M. Net loss totaled $107.2M vs. income of $1.74B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from $122.82 to -$6.93.